The late-stage precision oncology company said it would lay off 65% of its workforce and halt the launch of a Phase 1/2 MANTRA-4 combination trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,